Retatrutide

Phase 3Peptide

Retatrutide is a peptide that works as a Gip/glp-1/glucagon Triple Agonist.[2] It is being investigated across 6 indications, with its most advanced program in Phase 3.[1]

Retatrutide is one of 194 peptide programs targeting Type 2 Diabetes. It is currently in Phase 3.

Indications

Total Trials

Active Trials

193

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 DiabetesActive, not recruiting

Atherosclerotic Cardiovascular Disease (ASCVD)Active, not recruiting

OverweightRecruiting

ObesityActive, not recruiting

Diabetes MellitusActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

Type 2 DiabetesPhase 3

Active, not recruiting

Atherosclerotic Cardiovascular Disease (ASCVD)Phase 3

Active, not recruiting

OverweightPhase 3

Recruiting

ObesityPhase 3

Active, not recruiting

Diabetes MellitusPhase 3

Active, not recruiting

Type 2 Diabetes MellitusPhase 3

Active, not recruiting

Competition

Competitive Landscape

190 competitors in Obesity

#DrugCompanyPhaseTrials

Maridebart Cafraglutide

Amgen

Phase 3

7 2

Decadron

AAspen Global Incorporated

Phase 3

2 3

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1 4

Vivia

SSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Phase 3

1 5

Enavogliflozin

Daewoong Pharmaceutical Co. LTD.

Phase 3

1 6

Retatrutide

Eli Lilly

Phase 3

6 7

IBI362

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

4 8

Gemtesa

Sumitomo Pharma America, Inc.

Phase 3

1 9

Ribupatide

KKailera

Phase 3

3 10

PF-08653944

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Type 2 Diabetes

NCT06297603

Phase 3Active, not recruiting

Obesity

NCT06662383

Phase 1Active, not recruiting

Diabetes Mellitus

NCT06982859

Q1 2027

Phase 3Active, not recruiting

Type 2 Diabetes

NCT06260722

Q3 2027

Phase 3Recruiting

Overweight

NCT07232719

Phase 3Active, not recruiting

Obesity

NCT07035093

Clinical

Trials by Indication[1]

Obesity6 trials

A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT06859268·643 enrolled

A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT05929066·2,335 enrolled

Pre-approval Expanded Access of Retatrutide (LY3437943)

Available· Eli Lilly logo

Eli Lilly··NCT07629401

Show 3 more trials

A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT05882045·1,946 enrolled

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT07035093·586 enrolled

A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT06662383·800 enrolled

Type 2 Diabetes5 trials

Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT06354660·537 enrolled

Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT06260722·1,250 enrolled

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

Recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT07357415·600 enrolled

Show 2 more trials

A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled Trial

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT05929079·1,152 enrolled

A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes, Moderate or Severe Renal Impairment With Inadequate Glycemic Control on Basal Insulin With or Without Metformin and/or SGLT2 Inhibitor

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT06297603·320 enrolled

Overweight2 trials

Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight

Recruiting·HHudson Biotech·Phase 2·NCT07467447·300 enrolled

A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

Recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT07232719·250 enrolled

Chronic Kidney Disease1 trial

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT05936151·146 enrolled

Type 2 Diabetes Mellitus1 trial

A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 1·NCT06982846·78 enrolled

5 more indications

Osteoarthritis1 trial

A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT05931367·445 enrolled

Tics1 trial

To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT06808802·30 enrolled

Metabolic Dysfunction-Associated Steatotic Liver Disease1 trial

A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes

Recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT07165028·4,500 enrolled

Atherosclerotic Cardiovascular Disease (ASCVD)1 trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and Major Adverse Kidney Events in Participants With Body Mass Index ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT06383390·10,000 enrolled

Diabetes Mellitus1 trial

A Phase 1, Investigator- and Participant-Blinded Study to Evaluate the Effect of Retatrutide on α- and β- Cell Function and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 1·NCT06982859·95 enrolled

Sources

References

[1]
ClinicalTrials.gov — 20 trial records for Retatrutide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Retatrutide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Retatrutide. EMBL-EBI & Wellcome Sanger Institute.
[4]
PubMed — 2 publications indexed for Retatrutide. U.S. National Library of Medicine.
[5]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Gip/glp-1/glucagon Triple Agonist[2]
Modality: Peptide[2]
Highest Phase: Phase 3[1]
Company: Eli Lilly

Key Publications[4]

Retatrutide in Type 2 Diabetes: A Randomized Phase 2 Study

LancetJul 10, 2023DOI: 10.1016/S0140-6736(23)01254-8

Retatrutide, a Triple GIP/GLP-1/Glucagon Agonist, for Obesity: Phase 2 Trial

N Engl J MedJun 26, 2023DOI: 10.1056/NEJMoa2301972

Retatrutide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q3 2027

Trials by Indication[1]

Obesity6 trials

Type 2 Diabetes5 trials

Overweight2 trials

Chronic Kidney Disease1 trial

Type 2 Diabetes Mellitus1 trial

Osteoarthritis1 trial

Tics1 trial

Metabolic Dysfunction-Associated Steatotic Liver Disease1 trial

Atherosclerotic Cardiovascular Disease (ASCVD)1 trial

Diabetes Mellitus1 trial

References

Drug Info

Quick Facts

Key Publications[4]

Related News